Show simple item record

Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt

dc.contributor.authorAbozeid, Hassanein H.
dc.contributor.authorPaldurai, Anandan
dc.contributor.authorVarghese, Berin P.
dc.contributor.authorKhattar, Sunil K.
dc.contributor.authorAfifi, Manal A.
dc.contributor.authorZouelfakkar, Sahar
dc.contributor.authorEl-Deeb, Ayman H.
dc.contributor.authorEl-Kady, Magdy F.
dc.contributor.authorSamal, Siba K.
dc.date.accessioned2021-06-08T14:57:18Z
dc.date.available2021-06-08T14:57:18Z
dc.date.issued2019-02-11
dc.identifierhttps://doi.org/10.13016/7ebv-tihj
dc.identifier.citationAbozeid, H.H., Paldurai, A., Varghese, B.P. et al. Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt. Vet Res 50, 12 (2019).en_US
dc.identifier.urihttp://hdl.handle.net/1903/27137
dc.description.abstractInfectious bronchitis virus (IBV) causes a major disease problem for the poultry industry worldwide. The currently used live-attenuated vaccines have the tendency to mutate and/or recombine with circulating field strains resulting in the emergence of vaccine-derived variant viruses. In order to circumvent these issues, and to develop a vaccine that is more relevant to Egypt and its neighboring countries, a recombinant avirulent Newcastle disease virus (rNDV) strain LaSota was constructed to express the codon-optimized S glycoprotein of the Egyptian IBV variant strain IBV/Ck/EG/CU/4/2014 belonging to GI-23 lineage, that is prevalent in Egypt and in the Middle East. A wild type and two modified versions of the IBV S protein were expressed individually by rNDV. A high level of S protein expression was detected in vitro by Western blot and immunofluorescence analyses. All rNDV-vectored IBV vaccine candidates were genetically stable, slightly attenuated and showed growth patterns comparable to that of parental rLaSota virus. Single-dose vaccination of 1-day-old SPF White Leghorn chicks with the rNDVs expressing IBV S protein provided significant protection against clinical disease after IBV challenge but did not show reduction in tracheal viral shedding. Single-dose vaccination also provided complete protection against virulent NDV challenge. However, prime-boost vaccination using rNDV expressing the wild type IBV S protein provided better protection, after IBV challenge, against clinical signs and significantly reduced tracheal viral shedding. These results indicate that the NDV-vectored IBV vaccines are promising bivalent vaccine candidates to control both infectious bronchitis and Newcastle disease in Egypt.en_US
dc.description.urihttps://doi.org/10.1186/s13567-019-0631-5
dc.language.isoen_USen_US
dc.publisherSpringer Natureen_US
dc.titleDevelopment of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypten_US
dc.typeArticleen_US
dc.relation.isAvailableAtCollege of Agriculture & Natural Resourcesen_us
dc.relation.isAvailableAtDepartment of Veterinary Medicineen_us
dc.relation.isAvailableAtDigital Repository at the University of Marylanden_us
dc.relation.isAvailableAtUniversity of Maryland (College Park, MD)en_us


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record